← Back to Search

Unknown

MZE001 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Maze Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights

Summary

This trial tests a new drug called MZE001 to see if it is safe and how it behaves in the body. Healthy volunteers will take the drug in different doses and conditions (with and without food). Researchers will monitor how the drug is absorbed and if there are any side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with adverse events as a measure of safety and tolerability of MZE001
Secondary study objectives
AUC following multiple doses of MZE001
Accumulation ratio following multiple doses of MZE001
Maximum concentration following multiple doses of MZE001

Side effects data

From 2012 Phase 3 trial • 225 Patients • NCT01176240
13%
Headache
10%
Dizziness
9%
Nausea
7%
Fatigue
6%
Hypertension
5%
Contusion
5%
Excoriation
4%
Skin laceration
4%
Diarrhoea
4%
Oedema peripheral
4%
Blood pressure increased
1%
Abdominal pain upper
1%
Faecaloma
1%
Inguinal hernia
1%
Atrial fibrillation
1%
Bronchitis viral
1%
Upper respiratory tract infection bacterial
1%
Presyncope
1%
Mental status changes
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Droxidopa

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MZE001Experimental Treatment1 Intervention
MZE001 is a small molecule inhibitor of muscle glycogen synthase for the potential treatment of Pompe disease.
Group II: PlaceboPlacebo Group1 Intervention
Excipients containing no active ingredients.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MZE001
2022
Completed Phase 1
~130

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Maze TherapeuticsLead Sponsor
Sarah Noonberg, MDStudy DirectorMaze Therapeutics
~34 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top